drugset

drugset / Trial / NCT05524103

Study to Evaluate the Safety and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury

NCT05524103 ↗

Phase 1 Completed 24 enrolled AlaMab Therapeutics (Shanghai) Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of ALMB-0166 in patients with acute spinal cord injury.

Timeline

Start: 2022-04-15
Primary completion: 2025-02-08
Completion: 2025-02-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ALMB-0166	Unknown	—	—

Indications